No Decrease in Susceptibility to NVC-422 in Multiple-Passage Studies with Methicillin-Resistant Staphylococcus aureus, S. aureus, Pseudomonas aeruginosa, and Escherichia coli | Zendy

Louisa D’Lima | Zendy; Lisa Friedman | Zendy; Lu Wang | Zendy; Ping Xu | Zendy; Mark Anderson | Zendy; Dmitri Debabov | Zendy

Open Access

No Decrease in Susceptibility to NVC-422 in Multiple-Passage Studies with Methicillin-Resistant Staphylococcus aureus, S. aureus, Pseudomonas aeruginosa, and Escherichia coli

Author(s) -

Louisa D’Lima,

Lisa Friedman,

Lu Wang,

Ping Xu,

Mark Anderson,

Dmitri Debabov

Publication year - 2012

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.05985-11

Subject(s) - staphylococcus aureus , fusidic acid , mupirocin , microbiology and biotechnology , pseudomonas aeruginosa , escherichia coli , ciprofloxacin , methicillin resistant staphylococcus aureus , biology , antibiotics , bacteria , biochemistry , genetics , gene

Twenty-five serial passages of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus and 50 passages of methicillin-resistant Staphylococcus aureus resulted in no significant increase in NVC-422 MICs, while ciprofloxacin MICs increased 256-fold for E. coli and 32-fold for P. aeruginosa and S. aureus. Mupirocin, fusidic acid, and retapamulin MICs for MRSA increased 64-, 256-, and 16-fold, respectively. No cross-resistance to NVC-422 was observed with mupirocin-, fusidic acid-, and retapamulin-resistant strains.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research